Table 5.
Multivariate analysis of OS and PFS according to the first same RECIST-response
| In RECIST-PR patients |
In RECIST-SD patients |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS |
PFS |
OS |
PFS |
|||||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (yr) | ||||||||||||
| < 65 | 1 | 1 | 1 | 1 | ||||||||
| ≥ 65 | 0.89 | 0.58-1.37 | 0.60 | 0.72 | 0.48-1.06 | 0.10 | 1.45 | 0.90-2.33 | 0.13 | 0.82 | 0.49-1.34 | 0.43 |
| Sex | ||||||||||||
| Female | 1 | 1 | 1 | 1 | ||||||||
| Male | 0.83 | 0.54-1.28 | 0.40 | 0.81 | 0.56-1.17 | 0.27 | 0.62 | 0.38-1.00 | 0.05 | 1.30 | 0.74-2.26 | 0.36 |
| Location | ||||||||||||
| Colon/S-colon | 1 | 1 | 1 | 1 | ||||||||
| Rectum | 1.09 | 0.71-1.65 | 0.70 | 1.01 | 0.68-1.48 | 0.96 | 0.93 | 0.58-1.49 | 0.78 | 1.10 | 0.65-1.86 | 0.72 |
| Histological type | ||||||||||||
| Well/Moderate differentiation | 1 | 1 | 1 | 1 | ||||||||
| Poor differentiation/Mucinous/Signet ring cell | 1.19 | 0.66-2.14 | 0.57 | 1.07 | 0.64-1.78 | 0.80 | 2.07 | 1.17-3.65 | 0.01 | 1.14 | 0.61-2.12 | 0.68 |
| Metastatic presentation | ||||||||||||
| Metachronous | 1 | 1 | 1 | 1 | ||||||||
| Synchronous | 1.69 | 0.96-2.99 | 0.07 | 1.24 | 0.76-2.01 | 0.39 | 1.62 | 1.02-2.54 | 0.04 | 1.50 | 0.92-2.44 | 0.10 |
| No. of metastatic organs | ||||||||||||
| Only one (1) | 1 | 1 | 1 | 1 | ||||||||
| More than one (≥ 2) | 1.30 | 0.86-1.96 | 0.21 | 1.39 | 0.96-2.01 | 0.08 | 0.72 | 0.46-1.11 | 0.14 | 1.43 | 0.89-2.29 | 0.14 |
| First-line chemotherapy | ||||||||||||
| FOLFOX/FOLFIRI | 1 | 1 | 1 | 1 | ||||||||
| FOLFOX/FOLFIRI+targeting agent | 0.74 | 0.47-1.16 | 0.19 | 0.75 | 0.50-1.11 | 0.15 | 1.07 | 0.59-1.92 | 0.81 | 1.19 | 0.65-2.16 | 0.56 |
| CEA-response | ||||||||||||
| CEA-CR | 0.52 | 0.29-0.90 | 0.02 | 0.74 | 0.45-1.20 | 0.23 | 0.38 | 0.10-1.37 | 0.14 | 0.22 | 0.04-1.05 | 0.06 |
| CEA-PR | 1 | 1 | 0.53 | 0.30-0.93 | 0.03 | 0.48 | 0.25-0.92 | 0.03 | ||||
| CEA-SD | 3.13 | 1.69-5.78 | < 0.001 | 2.40 | 1.456-3.944 | 0.004 | 1 | 1 | ||||
| CEA-PD | 6.43 | 3.31-12.49 | < 0.001 | 3.81 | 2.287-6.334 | < 0.01 | 1.77 | 1.01-3.09 | 0.04 | 1.86 | 1.04-3.31 | 0.03 |
OS, overall survival; PFS, progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; HR, hazard ratio; CI, confidence interval; FOLFOX, oxaliplatin plus fluorouracil and leucovorin; FOLFIRI, cetuximab plus irinotecan, fluorouracil, and leucovorin; CEA, carcinoembryonic antigen; CR, complete response; PD, progressive disease.